
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
This publication highlights a scientific interchange held to evaluate recent data on therapeutic options for advanced gastric and gastroesophageal cancers, explore evidence-based therapy approaches and sequencing strategies in patients with HER2+ disease, and discuss methods to optimize treatment selection and management.






